Polaris (TPE:6550) unit Polaris Pharmaceuticals signed an exclusive license and distribution deal with Bioprofarma Bago for its cancer drug, ADI-PEG 20, according to a Friday Taiwan Exchange filing.
Shares gained about 3% recently in Taiwan.
The drug is used to treat Malignant Pleural Mesothelioma (MPM), a rare and aggressive cancer.
Under the eight-year agreement, Bioprofarma Bago will have exclusive rights to distribute the drug in the Latin American region.
Polaris said the deal is expected to generate revenue once shipments begin.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。